Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor

Naoyuki Komura, Yoko Ikeda, Natsuko Masuda, Yoji Umezawa, Keisuke Ito, Masahiro Kizaki, Kazuo Umezawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

All-trans retinoic acid (ATRA) induces the differentiation of acute promyelocytic leukemia (APL) cells into neutrophils. UF-1 cells were established from an ATRA-resistant APL patient, and were previously shown to possess a single amino acid (or nucleotide) substitution, Arg276Trp, in their ATRA receptor. In the present research, we designed several ATRA derivatives having a hydrophobic alkyl ketone moiety instead of the negatively charged carboxylic acid moiety. Among them the ethyl ketone derivative, Et-ketone ATRA, was shown to induce the differentiation of UF-1 cells when assessed in terms of intracellular ROS production. It also induced the formation of PML NBs and expression of CD11b antigen marker and p21, transcriptional targets of RARα. Et-ketone ATRA did not induce these phenotypic changes in wild-type APL NB4 cells. Furthermore, we found that Et-ketone ATRA induced apoptosis selectively in UF-1 cells, i.e., not in other leukemic cells. The induction of apoptosis was shown to be partly due to the up-regulation of Bax protein. Thus, Et-ketone ATRA selectively induced differentiation and apoptosis in ATRA-resistant APL UF-1 cells, and is likely to be useful for the clinical treatment of the Arg276Trp-type of ATRA-resistant APL.

Original languageEnglish (US)
Pages (from-to)301-313
Number of pages13
JournalLeukemia Research
Volume31
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Retinoic Acid Receptors
Tretinoin
Nucleotides
Ketones
Apoptosis
CD11b Antigens
bcl-2-Associated X Protein
Carboxylic Acids
Neutrophils
Up-Regulation
Amino Acids

Keywords

  • Acute promyelocytic leukemia (APL)
  • All-trans retinoic acid (ATRA)
  • Apoptosis
  • ATRA resistance
  • Differentiation
  • Et-ketone ATRA
  • Molecular design

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. / Komura, Naoyuki; Ikeda, Yoko; Masuda, Natsuko; Umezawa, Yoji; Ito, Keisuke; Kizaki, Masahiro; Umezawa, Kazuo.

In: Leukemia Research, Vol. 31, No. 3, 03.2007, p. 301-313.

Research output: Contribution to journalArticle

Komura, Naoyuki ; Ikeda, Yoko ; Masuda, Natsuko ; Umezawa, Yoji ; Ito, Keisuke ; Kizaki, Masahiro ; Umezawa, Kazuo. / Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. In: Leukemia Research. 2007 ; Vol. 31, No. 3. pp. 301-313.
@article{096b97da994d489ab6a683464e2e6f62,
title = "Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor",
abstract = "All-trans retinoic acid (ATRA) induces the differentiation of acute promyelocytic leukemia (APL) cells into neutrophils. UF-1 cells were established from an ATRA-resistant APL patient, and were previously shown to possess a single amino acid (or nucleotide) substitution, Arg276Trp, in their ATRA receptor. In the present research, we designed several ATRA derivatives having a hydrophobic alkyl ketone moiety instead of the negatively charged carboxylic acid moiety. Among them the ethyl ketone derivative, Et-ketone ATRA, was shown to induce the differentiation of UF-1 cells when assessed in terms of intracellular ROS production. It also induced the formation of PML NBs and expression of CD11b antigen marker and p21, transcriptional targets of RARα. Et-ketone ATRA did not induce these phenotypic changes in wild-type APL NB4 cells. Furthermore, we found that Et-ketone ATRA induced apoptosis selectively in UF-1 cells, i.e., not in other leukemic cells. The induction of apoptosis was shown to be partly due to the up-regulation of Bax protein. Thus, Et-ketone ATRA selectively induced differentiation and apoptosis in ATRA-resistant APL UF-1 cells, and is likely to be useful for the clinical treatment of the Arg276Trp-type of ATRA-resistant APL.",
keywords = "Acute promyelocytic leukemia (APL), All-trans retinoic acid (ATRA), Apoptosis, ATRA resistance, Differentiation, Et-ketone ATRA, Molecular design",
author = "Naoyuki Komura and Yoko Ikeda and Natsuko Masuda and Yoji Umezawa and Keisuke Ito and Masahiro Kizaki and Kazuo Umezawa",
year = "2007",
month = "3",
doi = "10.1016/j.leukres.2006.07.015",
language = "English (US)",
volume = "31",
pages = "301--313",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor

AU - Komura, Naoyuki

AU - Ikeda, Yoko

AU - Masuda, Natsuko

AU - Umezawa, Yoji

AU - Ito, Keisuke

AU - Kizaki, Masahiro

AU - Umezawa, Kazuo

PY - 2007/3

Y1 - 2007/3

N2 - All-trans retinoic acid (ATRA) induces the differentiation of acute promyelocytic leukemia (APL) cells into neutrophils. UF-1 cells were established from an ATRA-resistant APL patient, and were previously shown to possess a single amino acid (or nucleotide) substitution, Arg276Trp, in their ATRA receptor. In the present research, we designed several ATRA derivatives having a hydrophobic alkyl ketone moiety instead of the negatively charged carboxylic acid moiety. Among them the ethyl ketone derivative, Et-ketone ATRA, was shown to induce the differentiation of UF-1 cells when assessed in terms of intracellular ROS production. It also induced the formation of PML NBs and expression of CD11b antigen marker and p21, transcriptional targets of RARα. Et-ketone ATRA did not induce these phenotypic changes in wild-type APL NB4 cells. Furthermore, we found that Et-ketone ATRA induced apoptosis selectively in UF-1 cells, i.e., not in other leukemic cells. The induction of apoptosis was shown to be partly due to the up-regulation of Bax protein. Thus, Et-ketone ATRA selectively induced differentiation and apoptosis in ATRA-resistant APL UF-1 cells, and is likely to be useful for the clinical treatment of the Arg276Trp-type of ATRA-resistant APL.

AB - All-trans retinoic acid (ATRA) induces the differentiation of acute promyelocytic leukemia (APL) cells into neutrophils. UF-1 cells were established from an ATRA-resistant APL patient, and were previously shown to possess a single amino acid (or nucleotide) substitution, Arg276Trp, in their ATRA receptor. In the present research, we designed several ATRA derivatives having a hydrophobic alkyl ketone moiety instead of the negatively charged carboxylic acid moiety. Among them the ethyl ketone derivative, Et-ketone ATRA, was shown to induce the differentiation of UF-1 cells when assessed in terms of intracellular ROS production. It also induced the formation of PML NBs and expression of CD11b antigen marker and p21, transcriptional targets of RARα. Et-ketone ATRA did not induce these phenotypic changes in wild-type APL NB4 cells. Furthermore, we found that Et-ketone ATRA induced apoptosis selectively in UF-1 cells, i.e., not in other leukemic cells. The induction of apoptosis was shown to be partly due to the up-regulation of Bax protein. Thus, Et-ketone ATRA selectively induced differentiation and apoptosis in ATRA-resistant APL UF-1 cells, and is likely to be useful for the clinical treatment of the Arg276Trp-type of ATRA-resistant APL.

KW - Acute promyelocytic leukemia (APL)

KW - All-trans retinoic acid (ATRA)

KW - Apoptosis

KW - ATRA resistance

KW - Differentiation

KW - Et-ketone ATRA

KW - Molecular design

UR - http://www.scopus.com/inward/record.url?scp=33846039899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846039899&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2006.07.015

DO - 10.1016/j.leukres.2006.07.015

M3 - Article

C2 - 16968653

AN - SCOPUS:33846039899

VL - 31

SP - 301

EP - 313

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 3

ER -